Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Plus Standard Chemotherapy Versus Surufatinib Monotherapy in Patients With Pulmonary Neuroendocrine Tumors
NCT07357623Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in pulmonary neuroendocrine tumor, sponsored by Shanghai Chest Hospital. Started Sep 2025; status: recruiting.
02
Drugs
surufatinib
03
Conditions
pulmonary neuroendocrine tumor
Beyond the preview
Go deeper on NCT07357623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357623.